Mark Daniel Pegram
Impact in
- Oncology top 0.02%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Peptidase Inhibition and Analysis
- Cancer Research top 0.1%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
Papers in
- Oncology 118
- HER2/EGFR in Cancer Research 89
- Cancer Treatment and Pharmacology 22
- Peptidase Inhibition and Analysis 11
- Cancer-related Molecular Pathways 10
-
- Monoclonal and Polyclonal Antibodies Research 51
- Co-authors
- Dennis J. Slamon (32 shared papers)José Baselga (2 shared papers)Wolfgang EIERMANN (4 shared papers)Brian R Leyland-Jones (2 shared papers)Alex Bajamonde (2 shared papers)Virginia E. Paton (1 shared paper)Steven Shak (1 shared paper)Janet M. Wolter (1 shared paper)
- Journals
- Breast Cancer Research and Treatment (15 papers)Journal of Clinical Oncology (13 papers)Annals of Oncology (11 papers)Clinical Breast Cancer (10 papers)Clinical Cancer Research (8 papers)
- Partner nations
- United StatesGermanyUnited Kingdom
In The Last Decade
Mark Daniel Pegram
175 papers receiving 32.3k citations
Mark Daniel Pegram's Hit Papers
Peers
Comparison fields: 5 of 154
- Oncology 20.3k
- Cancer Research 6.5k
- Radiology, Nuclear Medicine and Imaging 8.2k
- Pulmonary and Respiratory Medicine 5.3k
- Genetics 1.5k
Countries citing papers authored by Mark Daniel Pegram
This map shows the geographic impact of Mark Daniel Pegram's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Daniel Pegram with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Daniel Pegram more than expected).
Fields of papers citing papers by Mark Daniel Pegram
This network shows the impact of papers produced by Mark Daniel Pegram. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Daniel Pegram. The network helps show where Mark Daniel Pegram may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark Daniel Pegram, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 181 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2 Hit paper breakdown → | 2001 | 9395 |
| 2 | American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer Hit paper breakdown → | 2006 | 3921 |
| 3 | Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer Hit paper breakdown → | 2012 | 3075 |
| 4 | American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer Hit paper breakdown → | 2007 | 1548 |
| 5 | Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer Hit paper breakdown → | 2019 | 971 |
| 6 | Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. Hit paper breakdown → | 1998 | 924 |
| 7 | Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer Hit paper breakdown → | 2009 | 838 |
| 8 | Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells Hit paper breakdown → | 2006 | 773 |
| 9 | 1999 | 586 | |
| 10 | Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial Hit paper breakdown → | 2017 | 537 |
| 11 | First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers Hit paper breakdown → | 2019 | 497 |
| 12 | 2003 | 488 | |
| 13 | 2004 | 431 | |
| 14 | Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. | 1994 | 391 |
| 15 | 1998 | 344 | |
| 16 | Mitochondrial copper depletion suppresses triple-negative breast cancer in mice Hit paper breakdown → | 2020 | 295 |
| 17 | 1997 | 276 | |
| 18 | Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer Hit paper breakdown → | 2021 | 273 |
| 19 | 2010 | 269 | |
| 20 | 2004 | 255 |
About Mark Daniel Pegram
Mark Daniel Pegram is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging, Cancer Research, Pulmonary and Respiratory Medicine and Molecular Biology, having authored 181 papers that have together received 33.8k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (89 papers), Monoclonal and Polyclonal Antibodies Research (51 papers), Breast Cancer Treatment Studies (26 papers), Cancer Treatment and Pharmacology (22 papers), Advanced Breast Cancer Therapies (14 papers), Glycosylation and Glycoproteins Research (13 papers), Peptidase Inhibition and Analysis (11 papers) and Cancer-related Molecular Pathways (10 papers). The work is most often cited by research in Oncology (20.3k citations), Cancer Research (6.5k citations), Radiology, Nuclear Medicine and Imaging (8.2k citations), Pulmonary and Respiratory Medicine (5.3k citations) and Genetics (1.5k citations). Mark Daniel Pegram has collaborated with scholars based in United States, Germany and United Kingdom. Frequent co-authors include Dennis J. Slamon, José Baselga, Wolfgang EIERMANN, Brian R Leyland-Jones, Alex Bajamonde, Virginia E. Paton, Steven Shak, Janet M. Wolter, Thomas Henry Fleming and Larry Norton. Their work appears in journals such as Breast Cancer Research and Treatment, Journal of Clinical Oncology, Annals of Oncology, Clinical Breast Cancer and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.